Genprex Osingo per osake

Mitä Genprex tekee? Genprex Inc is a clinical-stage gene therapy company headquartered in Austin, Texas, operating in the Health Care sector. Listed on March 29, 2018, the firm employs approximately 13 people and focuses on developing potentially life-changing technologies for patients with cancer and diabetes. Its lead product candidate, Oncoprex, is an immunogene therapy utilizing a tumor suppressor gene licensed from The University of Texas MD Anderson Cancer Center. This therapy is currently being developed for non-small cell lung cancer, often in combination with targeted or immunotherapies. Additionally, Genprex is researching a pre-clinical gene therapy licensed from the University of Pittsburgh, which aims to cure type 1 and type 2 diabetes. Genprex on yksi Eurpooliin suosituimmista yhtiöistä.